RESUMEN
Olanzapine is an atypical antipsychotic drug that has been increasingly used in acute treatment of, and therapeutic support for, schizophrenia, bipolar disorder and other psychoses. Considering that olanzapine acts on the dopaminergic receptor and this receptor is detected in germ cells, the present study aims to investigate the effects of treatment with different doses of olanzapine on spermatogenesis, plasma testosterone and weight of androgen-dependent organs in rats. Results showed reduced plasma testosterone levels, and reduced testis, epididymis and prostate weights. Histopathologic and histomorphometric analysis of spermatogenesis indicated testicular degeneration. Furthermore, germ cell desquamation, syncytial multinucleated cells, Sertoli cell vacuolization and presence of necrotic and apoptotic germ cells wwew observed. Olanzapine treatment in rats promoted endocrinological changes and lesions in the testis, leading to a disturbance in spermatogenesis.
Asunto(s)
Antipsicóticos/toxicidad , Benzodiazepinas/toxicidad , Enfermedades de los Genitales Masculinos/inducido químicamente , Espermatogénesis/efectos de los fármacos , Testículo/efectos de los fármacos , Animales , Apoptosis/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Recuento de Células , Epidídimo/efectos de los fármacos , Epidídimo/patología , Enfermedades de los Genitales Masculinos/sangre , Enfermedades de los Genitales Masculinos/patología , Letargia/inducido químicamente , Masculino , Necrosis/inducido químicamente , Necrosis/patología , Olanzapina , Tamaño de los Órganos/efectos de los fármacos , Próstata/efectos de los fármacos , Próstata/patología , Ratas , Ratas Wistar , Células de Sertoli/efectos de los fármacos , Células de Sertoli/patología , Espermatocitos/efectos de los fármacos , Espermatocitos/patología , Testículo/patología , Testosterona/sangreAsunto(s)
Acetaminofén/efectos adversos , Analgesia , Analgésicos no Narcóticos/efectos adversos , Analgésicos Opioides/efectos adversos , Lactancia Materna , Sistema Nervioso Central/efectos de los fármacos , Codeína/efectos adversos , Letargia/inducido químicamente , Oxicodona/efectos adversos , Periodo Posparto , Femenino , HumanosRESUMEN
OBJECTIVE: To quantify the incidence of central nervous system (CNS) depression in neonates breastfed by mothers medicated with oxycodone as compared with neonates whose breastfeeding mothers used codeine or acetaminophen only. STUDY DESIGN: We retrospectively compared 3 cohorts in 533 breastfeeding mother-infant pairs exposed to oxycodone (n = 139), codeine (n = 210), or acetaminophen only (n = 184). Standardized questionnaires were administered to mothers during the postpartum period to identify maternal and neonatal health outcomes temporally related to analgesia exposure. RESULTS: Maternal exposure to oxycodone during breastfeeding was associated with a 20.1% rate of infant CNS depression (28/139) compared with 0.5% in the acetaminophen group (1/184; P < .0001; OR, 46.16; 95% CI, 6.2-344.2) and 16.7% in the codeine group (35/210; P > .05; OR, 0.79; 95% CI, 0.46-1.38). Mothers of neonates with symptoms in the oxycodone and codeine cohorts took significantly higher doses of medication compared with mothers of infants with no symptoms in the same cohorts (P = .0005 oxycodone; median, 0.4 mg/kg/day; range, 0.03-4.06 mg/kg/day versus median, 0.15 mg/kg/day; range, 0.02-2.25 mg/kg/day; codeine P < .001; median, 1.4 mg/kg/day; range, 0.7-10.5 mg/kg/day versus 0.9 mg/kg/day; range, 0.18-5.8 mg/kg/day). Mothers were significantly more likely to experience sedative adverse effects from oxycodone as compared with codeine (P < .0001; OR, 17.62; 95% CI, 9.95-31.21). CONCLUSION: Oxycodone is not a safer alternative to codeine in breastfed infants.
Asunto(s)
Acetaminofén/efectos adversos , Analgesia , Analgésicos no Narcóticos/efectos adversos , Analgésicos Opioides/efectos adversos , Lactancia Materna , Sistema Nervioso Central/efectos de los fármacos , Codeína/efectos adversos , Letargia/inducido químicamente , Oxicodona/efectos adversos , Periodo Posparto , Adulto , Femenino , Humanos , Incidencia , Recién Nacido , Letargia/epidemiología , Estudios RetrospectivosAsunto(s)
Acetaminofén/efectos adversos , Analgesia , Analgésicos no Narcóticos/efectos adversos , Analgésicos Opioides/efectos adversos , Lactancia Materna , Sistema Nervioso Central/efectos de los fármacos , Codeína/efectos adversos , Letargia/inducido químicamente , Oxicodona/efectos adversos , Periodo Posparto , Femenino , HumanosAsunto(s)
Bromuros/envenenamiento , Cólico/tratamiento farmacológico , Fármacos Gastrointestinales/envenenamiento , Síndromes de Neurotoxicidad/etiología , Compuestos de Potasio/envenenamiento , Bromuros/historia , Seguridad de Productos para el Consumidor , República Dominicana/etnología , Embalaje de Medicamentos , Becas , Femenino , Fármacos Gastrointestinales/historia , Historia del Siglo XIX , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Recién Nacido , Letargia/inducido químicamente , Hipotonía Muscular/inducido químicamente , Síndromes de Neurotoxicidad/diagnóstico , Síndromes de Neurotoxicidad/fisiopatología , Síndromes de Neurotoxicidad/terapia , Ciudad de Nueva York , Medicamentos sin Prescripción , Centros de Control de Intoxicaciones , Compuestos de Potasio/historia , Reflejo Anormal , Toxicología , Resultado del TratamientoRESUMEN
The aim of this study was to determine the clinical, pathological and mycotoxicological effects of oral administration of fumonisin B1 (FB1) in rabbits. Eighteen rabbits were randomly assigned to two experimental groups: control group, 0 mg FB1; fumonisin group, 31.5 mg FB1/kg body weight, corresponding to about 630 mg FB1/kg diet. Fumonisin administered as a single oral dose to rabbits resulted in acute toxicity, significantly interfering with body and liver weight. Serum biochemical analysis revealed a significant increase of total protein, alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), urea and creatinine in the group receiving FB1 compared to control animals, a finding characterizing hepatic and renal injury in this group. Urinary protein concentrations were markedly elevated at 12, 24, 48 and 72 h after dosing, although visible pathological abnormalities were not observed, probably because of rapid repair of the damage. FB1 was detected in feces, with a maximum concentration at 24 h after administration, indicating that the enterohepatic circulation is important in rabbits. FB1 concentrations found in urine were low, with peak elimination at 12 h after intoxication. The highest FB1 concentrations were observed in feces compared to urine and liver, demonstrating that feces are the main routes of excretion.